Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print December 14, 2007
DOI: 10.2337/db07-1230

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-1230v1
57/3/688    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cherney, D.
Right arrow Articles by Sochett, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cherney, D.
Right arrow Articles by Sochett, E.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

The Effect of Cyclooxygenase 2 Inhibition on Renal Hemodynamic Function in Humans with Type 1 Diabetes Mellitus

DZI Cherney1, JA Miller1, JW Scholey1, TJ Bradley2, C Slorach2, JR Curtis3, MG Dekker3, R Nasrallah4, RL Hébert4, and EB Sochett3

1 Division of Nephrology, Toronto General Hospital, University of Toronto
2 Division of Cardiology, Hospital for Sick Children, University of Toronto
3 Division of Endocrinology, Hospital for Sick Children, University of Toronto
4 Department of Cellular and Molecular Medicine, Kidney Research Centre, Faculty of Medicine, University of Ottawa

Objective: Studies in animal models suggest that cyclooxygenase-2 (COX2) plays a role in the regulation of the renal microcirculation in diabetes mellitus (DM). Accordingly, we examined the role of COX2 in the control of renal hemodynamic function and in the renal response to hyperglycemia in humans with uncomplicated type 1 DM. We hypothesized that COX2 inhibition would alleviate the hyperfiltration state and would abrogate the hyperglycemia-mediated rise in GFR.

Research Design and Methods: Renal function was assessed during clamped euglycemia and hyperglycemia on two consecutive days before, and then again after, 14 days of COX2 inhibition using celecoxib (200 mg PO OD). For analysis, the cohort was then divided into two groups [graphic][graphic]based on the baseline glomerular filtration rate (GFR): 9 subjects exhibited hyperfiltration (HF) (GFR [graphic]135 ml/min/1.73m2) and 12 subjects exhibited normofiltration (NF) (GFR < 135 ml/min/1.73 m2).

Results: Under euglycemic conditions, COX2 inhibition resulted in a significant decline in GFR in the HF group (150[graphic]5 to 139[graphic]5 ml/min/1.73 m2), but increased GFR in the NF group (118[graphic]5 to 138[graphic]5 ml/min/1.73 m2). COX2 inhibition did not blunt the hyperglycemia-associated rise in GFR in the NF group, and was instead associated with an augmented rise in GFR.

Conclusions: In summary, our results support the hypothesis that COX2 is an important determinant of renal hemodynamic function in subjects with type 1 DM. The renal response to COX2 inhibition emphasizes that HF and NF are distinct physiologic groups.


Correspondence: judith.miller{at}utoronto.ca

Correspondence: judith.miller{at}utoronto.ca

Key Words: Type 1 Diabetes Mellitus • Glomerular Filtration Rate • Cyclooxygenase 2 inhibition • Renal hyperfiltration • Renin angiotensin system


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.